Ownership and insider activity for Neumora Therapeutics, Inc. Common Stock (NMRA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder.
Price
| Price | $0.77 |
| Market Cap | $143M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-20 | Aurora Daljit Singh | A-Award | 200,000 | $304K |
| 2026-08-20 | Aurora Daljit Singh | M-Exempt | 67,741 | $49K |
| 2026-08-20 | Aurora Daljit Singh | M-Exempt | 21,685 | $16K |
| 2026-08-20 | Aurora Daljit Singh | M-Exempt | 67,741 | $49K |
| 2026-08-21 | Aurora Daljit Singh | M-Exempt | 21,055 | $15K |
| 2026-08-21 | Aurora Daljit Singh | M-Exempt | 20,553 | $15K |
| 2026-08-21 | Aurora Daljit Singh | M-Exempt | 20,553 | $15K |
| 2026-08-20 | Aurora Daljit Singh | M-Exempt | 45,026 | $32K |
| 2026-08-20 | Aurora Daljit Singh | S-Sale | 67,741 | $103K |
| 2026-08-21 | Aurora Daljit Singh | S-Sale | 20,553 | $33K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 0 | $192.0M | $409.2M | $240.9M | $374.0M | $142.1M | $182.5M |
| Short-term Investments | 0 | 0 | 0 | $130.9M | $79.9M | $165.4M | 0 |
| Receivables | 0 | $148000 | $200000 | $919000 | $939000 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 0 | $193.8M | $415.6M | $388.0M | $478.3M | $314.1M | $190.5M |
| Property, Plant & Equipment | 0 | $3.9M | $4.0M | $10.6M | $6.9M | $2.9M | $457000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 0 | $197.9M | $429.3M | $426.2M | $496.2M | $317.0M | $191.0M |
| Accounts Payable | 0 | $2.4M | $1.6M | $7.1M | $337000 | $3.3M | $3.4M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $284000 |
| Total Current Liabilities | $21000 | $9.4M | $23.3M | $23.7M | $25.1M | $29.9M | $32.5M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $193000 |
| Total Liabilities | $21000 | $292.3M | $754.5M | $873.1M | $27.1M | $29.9M | $87.2M |
| Retained Earnings | -$21000 | -$99.3M | -$336.6M | -$467.5M | -$703.4M | -$947.2M | -$1.18B |
| Total Equity | -$21000 | -$94.4M | -$325.2M | -$446.9M | $469.1M | $287.1M | $103.9M |
| Total Debt | 0 | $2.0M | $2.1M | $8.4M | $5.2M | $1.9M | $477000 |
| Net Debt | 0 | -$189.9M | -$407.2M | -$363.4M | -$448.8M | -$305.7M | -$182.1M |
| Working Capital | -$21000 | $184.5M | $392.3M | $364.3M | $453.2M | $284.2M | $158.1M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 4.50 |
Profitability
| Return on Equity | -242.28% |
| Return on Invested Capital | -216.05% |
| Return on Assets | -169.86% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADCT · ALMS · AUTL · BCYC · FDMT · FULC · LXRX
Explore sector: Healthcare · Biotechnology
More sections of NMRA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks